J. Christopher  Barry net worth and biography

J. Christopher Barry Biography and Net Worth

CEO of NuVasive
Chris Barry serves as our chief executive officer and a member of the NuVasive Board of Directors.

Prior to this role, Mr. Barry served as senior vice president and president of surgical innovations at Medtronic, its second largest business unit with $5.5 billion in annual revenue, from 2015 to 2018. In this role, Chris provided strategic direction to more than 14,000 employees working in 78 countries, including 10 manufacturing sites and multiple R&D centers. Prior to the acquisition of Covidien by Medtronic, Mr. Barry was president, Advanced Surgical Technologies of Covidien, where he led global strategy, product portfolio and U.S. commercial teams for the $3.2 billion global business unit. Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Mr. Barry received a bachelor’s degree in environmental science from Texas Tech University.

What is J. Christopher Barry's net worth?

The estimated net worth of J. Christopher Barry is at least $2.00 million as of April 13th, 2022. Mr. Barry owns 50,218 shares of NuVasive stock worth more than $1,996,166 as of April 24th. This net worth evaluation does not reflect any other investments that Mr. Barry may own. Additionally, Mr. Barry receives an annual salary of $3,080,000.00 as CEO at NuVasive. Learn More about J. Christopher Barry's net worth.

How old is J. Christopher Barry?

Mr. Barry is currently 50 years old. There are 4 older executives and no younger executives at NuVasive. Learn More on J. Christopher Barry's age.

What is J. Christopher Barry's salary?

As the CEO of NuVasive, Inc., Mr. Barry earns $3,080,000.00 per year. Learn More on J. Christopher Barry's salary.

How do I contact J. Christopher Barry?

The corporate mailing address for Mr. Barry and other NuVasive executives is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. NuVasive can also be reached via phone at (858) 909-1800 and via email at [email protected]. Learn More on J. Christopher Barry's contact information.

Has J. Christopher Barry been buying or selling shares of NuVasive?

J. Christopher Barry has not been actively trading shares of NuVasive during the last ninety days. Most recently, James Christopher Barry sold 5,000 shares of the business's stock in a transaction on Wednesday, April 13th. The shares were sold at an average price of $58.00, for a transaction totalling $290,000.00. Following the completion of the sale, the chief executive officer now directly owns 50,218 shares of the company's stock, valued at $2,912,644. Learn More on J. Christopher Barry's trading history.

Who are NuVasive's active insiders?

NuVasive's insider roster includes J. Christopher Barry (CEO), Massimo Calafiore (EVP), and Lucas Vitale (Insider). Learn More on NuVasive's active insiders.

J. Christopher Barry Insider Trading History at NuVasive

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/13/2022Sell5,000$58.00$290,000.0050,218View SEC Filing Icon  
3/28/2022Sell5,000$55.00$275,000.00View SEC Filing Icon  
6/25/2021Sell5,000$70.00$350,000.00View SEC Filing Icon  
6/21/2021Sell5,000$68.00$340,000.00View SEC Filing Icon  
See Full Table

J. Christopher Barry Buying and Selling Activity at NuVasive

This chart shows James Christopher Barry's buying and selling at NuVasive by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NuVasive Company Overview

NuVasive logo
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.
Read More

Today's Range

Now: $39.75
Low: $39.75
High: $39.75

50 Day Range

MA: $39.64
Low: $38.12
High: $40.66

2 Week Range

Now: $39.75
Low: $35.17
High: $49.53

Volume

N/A

Average Volume

1,159,125 shs

Market Capitalization

$2.08 billion

P/E Ratio

79.50

Dividend Yield

N/A

Beta

1.07